Answers are grounded in this paper and cite their sources.
Industrial rAAV purification comprises an affinity capture step to isolate the capsids from crude lysates and a polishing anion‐exchange step to enrich transgene‐loaded (full) capsids. Current immuno‐affinity ligands offer high capacity and selectivity but cannot discriminate full from empty capsids, and require acid elution that can compromise product activity and hinder integration with the polishing step. This work introduces rationally designed, mixed‐mode peptide ligands that target motifs conserved across AAV serotypes and exploit the structural and electrostatic features of gene‐loaded capsids to enrich cell‐transducing virions under mild elution conditions. Immobilized on chromatographic resins, the selected ligands capture AAV2, AAV5, AAV8, and AAV9 directly from HEK293 lysates at loads of 1–2 × 10 14 capsids per mL of resin, and release them at near‐physiological pH (6.0–6.5), affording up to 70% yield and 7‐fold enrichment of cell‐transducing virions, > 100‐fold reduction of host cell proteins, and residual host cell DNA on par with the immunoaffinity benchmark (< 28 ng/mL). Every peptide‐functionalized resin sustained twelve bind‐elute cycles with cleaning‐in‐place in 0.1 M NaOH (aq.) without loss of binding capacity, yield of transduction‐competent virions, or impurity clearance. By consolidating the purification and enrichment of gene‐loaded capsids into the capture step, this platform enhances product quality while reducing manufacturing costs, offering a cost‐effective alternative to conventional affinity technologies.
No takes yet. Share an insight, caveat, or question.
Minzoni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: